NASDAQ · IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES · SMALL CAP
Insight Molecular Diagnostics Inc. IMDX
12 fiscal years on record · USD · FY2025 reported
SEC FILINGS ONLY
Revenue · FY2025
$4.1M
▲ 115.6% vs FY2024
EPS · FY25
$-1.65
Dividend / sh · FY25
—
Payout · FY25
—
ROE · FY25
—
Net margin · FY25
-1238.5%
Dividend coverage
—
Advertisement
AdSense · Leaderboard 728×90320×100
Result
USD 4.1M
Revenue, FY2025 · full 12-year series below
Revenue
Net income
The company lost 1239 cents on every revenue dollar this year.
Per share
USD -1.65
Diluted EPS, FY2025
EPS
The company pays no cash dividend.
Profitability
—
Return on equity, FY2025
ROE
Operating margin-1260.8%
Net margin-1238.5%
Return on assets-165.1%
Returned to shareholders
—
returned in FY2025 · dividends + net buybacks
Dividends paid—
Net buybacks—
Share of profit—
Consecutive raises—
Growth
+27.2% a year
revenue, compounded over five years
CAGR
3 yrs
5 yrs
10 yrs
15 yrs
Revenue
+61.8%
+27.2%
Compound annual rates per period — left blank where the series crosses a loss.
Share base
0.03B
Shares outstanding, FY2025
Change, 5 years+221.0%
Change, 10 years—
The share count grew 221% in five years — the same company, cut into more, smaller slices.
Advertisement
AdSense · Leaderboard 728×90300×250
Balance sheet
USD 25.8M
total assets, end of FY2025
Total assetsUSD 25.8M
EquityUSD -31.5M
CashUSD 11.6M
Current ratio1.27×
Equity funds -122% of total assets.
History
12 fiscal years
Every figure from documents filed with the SEC · USD
Metric
2025
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
Revenue $B
0.0
0.0
0.0
0.0
0.0
0.0
·
·
·
·
·
·
Operating income $B
−0.1
−0.1
−0.0
−0.0
−0.1
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
EBITDA $B
−0.0
−0.1
−0.0
−0.0
−0.1
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
Income tax $B
0.0
0.0
0.0
·
−0.0
−0.0
·
·
·
·
·
·
Net income $B
−0.1
−0.1
−0.0
−0.1
−0.1
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
EPS, diluted $
−1.65
−4.66
−3.75
−13.25
−0.72
−0.46
−0.44
−0.42
−0.64
−0.42
−0.42
−0.27
Dividend / sh $
·
·
·
·
·
·
·
·
·
·
·
·
Payout %
·
·
·
·
·
·
·
·
·
·
·
·
ROE %
·
−1480.7
−101.5
−146.5
−129.9
−93.1
−130.9
−402.6
−271.6
−110.1
−187.0
·
Shares out B
0.03
0.02
0.01
0.01
0.09
0.07
0.06
0.04
0.03
0.03
0.03
·
Slide the table for earlier years · "·" marks figures not disclosed in the filing for that year.
How we verifyAUDITED
36 of 40
checks passed before publication
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidity
Every figure was compared against the original statement: 0 failures and 4 presentation gaps.
What we don’t show
We’d rather say what’s missing than fill the gap with an estimate.
P/E rationeeds a market quote — not yet licensed
Market capitalizationneeds a market quote — not yet licensed
Dividend yieldneeds a market quote — not yet licensed
Price-to-bookneeds a market quote — not yet licensed